08 Sep, 2022 Results from APOLLO-B Phase 3 Study of Patisiran Presented at ISA

During a late-breaker session at the 18^th International Symposium on Amyloidosis, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Read the press release
Maurer, et al. “Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy”

(more…)

29 Aug, 2022 New Results from Phase 2 Study of Investigational Cemdisiran Presented at EMCHD

During the 18^th European Meeting on Complement in Human Disease (EMCHD), taking place August 26-28, 2022, we presented new results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is being developed in collaboration with Regeneron Pharmaceuticals for the treatment of immunoglobulin A nephropathy.

Read the press release
Barratt, et al. “Results from the Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy”

02 Aug, 2022 ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology.

Read the paper in the Pediatric Nephrology

23 Jul, 2022 HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

Eighteen-month efficacy and safety results from the HELIOS-A Phase 3 study of AMVUTTRA™ (vutrisiran), an RNAi therapeutic recently approved in the U.S. for adults with the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, were published in Amyloid.

Read the paper in Amyloid

20 Jul, 2022 ILLUMINATE-C Phase 3 Results for Lumasiran Published in American Journal of Kidney Diseases

Results from the six-month primary analysis of the ongoing ILLUMINATE-C Phase 3 study of lumasiran in patients of all ages with primary hyperoxaluria type 1 (PH1) and advanced kidney disease were published online in the American Journal of Kidney Diseases.

Read the paper in the American Journal of Kidney Diseases

24 May, 2022 New Results from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at ERA-EDTA

New results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) were presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress (May 19-22, 2022).

Findings from a separate pooled pharmacokinetic and pharmacodynamic analysis of data from four clinical trials of lumasiran were also presented.

Read the press release
Groothoff, et al. “Lumasiran for Patients With Primary Hyperoxaluria Type 1 With Impaired Kidney Function: Data From the 6-Month Analysis of the Phase 3 ILLUMINATE-C Trial”
Gansner, et al. “Pharmacokinetics and Pharmacodynamics of Lumasiran: Analysis of Four Clinical Studies”

23 May, 2022 New 18-Month Exploratory Cardiac Results from HELIOS-A Phase 3 Study of Vutrisiran

During the annual Heart Failure congress of the Heart Failure Association of the European Society of Cardiology, taking place May 21-24, 2022, we presented new 18-month results from the exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis.

Read the press release
Garcia-Pavia, et al. “HELIOS-A: 18-Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis”

16 May, 2022 News Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at PNS 2022

New results from the HELIOS-A study of vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented during the Peripheral Nerve Society (PNS) 2022 Annual Meeting, taking place May 14-17, 2022.

Ajroud-Driss, et al. “HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin-Mediated Amyloidosis”

11 May, 2022 Preclinical Results on Alnylam’s Novel C16 Conjugate Technology for Delivery of siRNAs to the Central Nervous System Presented at TIDES USA 2022 Meeting

New results on Alnylam’s platform advancements enabling delivery of therapeutic short interfering RNAs (siRNAs) to the central nervous system (CNS) were presented at the TIDES USA, Oligonucleotide & Peptide Therapeutics 2022 Meeting being held in Boston on May 9-12. Additional preclinical data were presented on Alnylam’s GEMINI platform for simultaneous silencing of two transcripts within the CNS with a single siRNA entity.

Thiel CS., “Recent Advancements for the Delivery of siRNAs to the Central Nervous System”

25 Apr, 2022 New Results from 12M Analysis of ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) Presented at PAS 2022

New results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO^® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were presented at the Pediatric Academic Societies (PAS) 2022 Meeting (April 21-25, 2022).

Michael, et al. “Efficacy and Safety of Lumasiran for Infants and Young Children With Primary Hyperoxaluria Type 1: 12-Month Analysis of the Phase 3 ILLUMINATE-B Trial”